202 related articles for article (PubMed ID: 15470272)
1. Cardiovascular toxicity with highly active antiretroviral therapy: review of clinical studies.
Bozkurt B
Cardiovasc Toxicol; 2004; 4(3):243-60. PubMed ID: 15470272
[TBL] [Abstract][Full Text] [Related]
2. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management.
Neto MG; Zwirtes R; Brites C
Braz J Infect Dis; 2013; 17(6):691-700. PubMed ID: 23916459
[TBL] [Abstract][Full Text] [Related]
3. [Cardiovascular risk factors associated with antiretroviral therapy].
Pérez-Camacho I; Camacho A; Torre-Cisneros J; Rivero A
Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():24-32. PubMed ID: 20172412
[TBL] [Abstract][Full Text] [Related]
4. Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection.
Koppel K; Bratt G; Eriksson M; Sandström E
Int J STD AIDS; 2000 Jul; 11(7):451-5. PubMed ID: 10919487
[TBL] [Abstract][Full Text] [Related]
5. HIV infection, highly active antiretroviral therapy and the cardiovascular system.
Barbaro G
Cardiovasc Res; 2003 Oct; 60(1):87-95. PubMed ID: 14522410
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of coronary atherosclerotic risk and plaque burden in HIV patients: 'a call for cardiovascular prevention'.
Acevedo M; Sprecher DL; Calabrese L; Pearce GL; Coyner DL; Halliburton SS; White RD; Sykora E; Kondos GT; Hoff JA
Atherosclerosis; 2002 Aug; 163(2):349-54. PubMed ID: 12052482
[TBL] [Abstract][Full Text] [Related]
7. [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].
Hirsch HH; Battegay M
Dtsch Med Wochenschr; 2003 May; 128(19):1051-4. PubMed ID: 12736856
[TBL] [Abstract][Full Text] [Related]
8. HIV and increased risk of cardiovascular diseases.
Das S
Sex Health; 2005; 2(4):219-21. PubMed ID: 16402668
[TBL] [Abstract][Full Text] [Related]
9. Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk.
Barbaro G; Barbarini G
Chemotherapy; 2006; 52(4):161-5. PubMed ID: 16675900
[TBL] [Abstract][Full Text] [Related]
10. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Grinspoon SK
Am J Med; 2005 Apr; 118 Suppl 2():23S-28S. PubMed ID: 15903292
[TBL] [Abstract][Full Text] [Related]
12. Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART.
Cahn P; Leite O; Rosales A; Cabello R; Alvarez CA; Seas C; Carcamo C; Cure-Bolt N; L'Italien GP; Mantilla P; Deibis L; Zala C; Suffert T
Braz J Infect Dis; 2010; 14(2):158-66. PubMed ID: 20563442
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study.
Aboud M; Elgalib A; Pomeroy L; Panayiotakopoulos G; Skopelitis E; Kulasegaram R; Dimian C; C Lampe F; Duncan A; Wierzbicki AS; Peters BS
Int J Clin Pract; 2010 Aug; 64(9):1252-9. PubMed ID: 20653801
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival.
Leonard EG; McComsey GA
Infect Dis Clin North Am; 2005 Sep; 19(3):713-29. PubMed ID: 16102657
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
[TBL] [Abstract][Full Text] [Related]
16. HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era.
Ballocca F; Gili S; D'Ascenzo F; Marra WG; Cannillo M; Calcagno A; Bonora S; Flammer A; Coppola J; Moretti C; Gaita F
Prog Cardiovasc Dis; 2016; 58(5):565-76. PubMed ID: 26943980
[TBL] [Abstract][Full Text] [Related]
17. Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.
Calza L; Manfredi R; Pocaterra D; Chiodo F
J Infect; 2008 Jul; 57(1):16-32. PubMed ID: 18358535
[TBL] [Abstract][Full Text] [Related]
18. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy.
Barbaro G
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Aug; 5(4):337-43. PubMed ID: 16101566
[TBL] [Abstract][Full Text] [Related]
19. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular complications in HIV management: past, present, and future.
Aberg JA
J Acquir Immune Defic Syndr; 2009 Jan; 50(1):54-64. PubMed ID: 19295335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
